Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Whitehawk Therapeutics, Inc.

WHWK ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$3.25

▼ -1.07%

Market Cap $185.28M · Vol 101.97K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$185.28M

Micro Cap

Div Yield

N/A

EPS Growth

-179.05%

YoY

RSI (14)

35.94

Momentum

Beta

0.97

vs Market

52W High

$5.48

40.05% below

52W Low

$1.97

66.75% above

Volume

101.97K

Avg 137.38K

P/B

0.84

Price-to-book

ROE

N/A

Return on equity

Free Float

80.47%

Public shares

Shariah Compliance8 STANDARDS

✗ Whitehawk Therapeutics, Inc. (WHWK) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does WHWK pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.91%

-19.55%

-18.55%

-23.17%

YTD

+34.30%

+37.13%

-17.51%

-88.00%

Financials & Valuation

TTM · Annual

Total Revenue	$7.15M
Net Income	$-20,596,000.00
Revenue Growth (YoY)	N/A
Gross Margin	89.36%
Operating Margin	-1,601.12%
Net Profit Margin	-288.26%
ROE	N/A
ROA · ROIC	-18.63% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	15.97
P/B	0.84
P/FCF	N/A
EPS Growth	-179.05%
Outstanding Shares	57.01M

Technical Indicators

50-Day SMA	$4.03
200-Day SMA	$3.82
RSI (14)	35.94
Beta	0.97
52-Week High	$5.48
52-Week Low	$1.97

Volume Today	101.97K
Avg Daily Volume (30D)	137.38K
Relative Volume	0.74x
Volatility (10D)	76.64
Volatility (30D)	53.12
Free Float	80.47%

Analyst Consensus

BUY

Current Price $3.25

Mean Target $7.71

52W Low$1.97 52W High$5.48

Current

Target

$1.97 $5.48

Current Analyst target

+137.36% upside potential · 9 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG002WN7DV9

ISINUS00032Q1040

CountryUSA

Sub-IndustryBiopharmaceuticals

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

REGN Regeneron Pharmaceuticals, Inc. +1.67% CSL.AX CSL Limited +0.03% UCB.BR Ucb SA +21.64% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. -3.95% BIIB Biogen Inc. +5.34%

Company Profile

Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.